Giovanni Barosi

TL;DR: Post‐hoc analyses of the impact of ruxolitinib on disease‐related symptoms and HRQoL in MF patients from the large phase 3 COMFORT‐II study demonstrated that ruxolinib improved HRQeL inMF patients and further support the use of rUXolit inib for the treatment of symptomatic MF.

TL;DR: Low-molecular-weight heparin might be a cost-effective drug for secondary prophylaxis of venous thromboembolism, especially in patients at high risk of recurrence and where the drug's cost is lower.

TL;DR: Overall, these recommendations can be used for a proper and safe application of polyclonal ATG/ATLG to prevent GvHD after allogeneic HSCT to prevent graft-versus-host disease.

TL;DR: The Hemox-Analyzer is a simple, quick and reliable instrument for recording the oxyhemoglobin dissociation curve that shows good precision and both the P50 value and observation of the fine structure of the curve can furnish information about the delivery of oxygen to tissues.

TL;DR: The findings indicate that the operative risk of splenectomy for both mortality and morbidity was unpredictable and suggest trials for prophylactic cytoreductive treatment in young patients and when platelet count is normal to increased.